HACKENSACK, N.J., Nov. 7, 2017 /PRNewswire/ -- Champions Oncology,
Inc. (Nasdaq: CSBR), engaged in the development of advanced
technology solutions and services to personalize the development
and use of oncology drugs, will be participating in the 8th Annual
Craig-Hallum Alpha Select Conference on November 16th. The conference is being held at
the Sheraton New York Times Square Hotel in New York City.
Management will host one-on-one meetings throughout the day. To
schedule a meeting, please contact your Craig-Hallum
representative, or Hayden IR.
About Champions Oncology, Inc.
Champions Oncology, Inc. is engaged in the development of
advanced technology solutions and services to personalize the
development and use of oncology drugs. The Company's TumorGraft
technology platform is a novel approach to personalizing cancer
care based upon the implantation of primary human tumors in immune
deficient mice followed by propagation of the resulting
engraftments, or TumorGrafts, in a manner that preserves the
biological characteristics of the original human tumor in order to
determine the efficacy of a treatment regimen. The Company
uses this technology in conjunction with related services to offer
solutions for two customer groups: Personalized Oncology
Solutions, in which results help guide the development of
personalized treatment plans, and Translational Oncology Solutions,
in which pharmaceutical and biotechnology companies seeking
personalized approaches to drug development can lower the cost and
increase the speed of developing new drugs. TumorGrafts are
procured through agreements with a number of institutions in the
U.S. and overseas as well as through Champions' Personalized
Oncology Solutions business. For more information, please visit
www.championsoncology.com.
Contact:
James Carbonara
Hayden IR
(646)-755-7412
james@haydenir.com
Brett Maas
Hayden IR
(646) 536-7331
brett@haydenir.com
View original
content:http://www.prnewswire.com/news-releases/champions-oncology-to-participate-in-the-craig-hallum-alpha-select-investor-conference-300550501.html
SOURCE Champions Oncology, Inc.